Oral JAK inhibitors vs biologics for eczema
When atopic dermatitis remains troublesome despite an appropriate skin-care and topical-treatment plan, systemic treatment may be considered. Oral JAK inhibitors and injectable biologics differ in how they work, their risks and the follow-up they require.
On this page
First establish why treatment needs to change
Persistent itch, lost sleep, widespread inflammation and repeated flares can justify a discussion beyond creams. The dermatologist should review the diagnosis and how previous treatments were used before selecting a systemic medicine.
Bring a list of products and prescriptions, how long you used them and why you stopped. Photographs of a severe flare can help when the skin happens to be calmer on the appointment day. Describe the effect on sleep and daily activities as well as the affected body area.
Sources and references: [1]
How biologic treatment works
Biologics target specific inflammatory signals. Dupilumab is an example used for atopic dermatitis; other biologics act on different parts of the inflammatory pathway. These treatments are given by injection, with schedules that depend on the drug and the patient's circumstances.
The consultation should cover injection training and how you will obtain future doses. Dupilumab can cause injection-site reactions and eye problems such as conjunctivitis. Tell the dermatologist about existing eye symptoms, and ask whom to contact if they appear or worsen during treatment.
Sources and references: [1]
How oral JAK inhibitors differ
Oral JAK inhibitors, including abrocitinib and upadacitinib, act on signaling pathways within cells. They are tablet options for selected patients with atopic dermatitis. Age eligibility, prior-treatment requirements and licensed uses vary by medicine and country.
For a Shanghai consultation, ask about the specific product rather than the class name alone. The team needs to check the applicable local indication and whether your health history makes it a reasonable option. A tablet can be convenient, but convenience is only part of the comparison.
Put the safety warnings into your own context
Oral JAK treatment requires a careful discussion of infections and other serious risks. Class warnings include major cardiovascular events, cancer, blood clots and death. Smoking history, previous clots, cardiovascular disease and other illnesses can affect the balance of benefit and risk.
The original FDA safety comparison involved tofacitinib in an older rheumatoid arthritis population with cardiovascular risk factors. Those results should not be presented as the personal risk of a young person with eczema. They do explain why the prescriber reviews the full medical history instead of choosing solely on skin symptoms.
Ask what checks are required before the first dose
Tell the team about past serious infections, shingles, cancer, cardiovascular problems and all medicines or supplements. Discuss pregnancy plans before starting treatment. The prescriber should explain the screening and monitoring required for the chosen product.
Ask for the follow-up schedule in writing: which tests are needed, when treatment response will be reviewed and which symptoms require prompt contact. If you live outside China, identify who will order tests and review results at home. Starting treatment is much easier to plan when continuing care is already clear.
Sources and references: [2]
Compare the daily burden as well as the skin response
An injection schedule may suit one person, while another strongly prefers tablets. Eye symptoms, needle concerns, travel, storage arrangements and repeat monitoring can all affect the choice. Ask how the expected benefit will be measured and when an inadequate response would lead to another discussion.
Keep a simple record of itch, sleep and the treatments needed for flares. The aim is to understand whether life is getting easier, not to create a perfect daily score. Agree with the clinician which changes are meaningful enough to justify continuing the treatment.
Skin care and other options still matter
Systemic treatment usually sits alongside moisturizers and a plan for topical treatment when needed. Phototherapy and other systemic medicines may also enter the comparison. The decision is not limited to the two classes in this article.
Ask how to manage an ordinary flare, what to do if infection is suspected and how prescriptions will be renewed. Avoid combining or switching systemic treatments on your own. Our broader atopic dermatitis escalation guide explains the steps that can lead to this treatment discussion.
Sources and references: [1]
Preparing a Shanghai dermatology review
Huashan Hospital has a dermatology specialty and is a relevant resource for complex eczema assessment. The enquiry should include your age, current treatment, previous systemic medicines and the main reason you want a change.
EastMedGo can help organize a treatment timeline, photographs and available test results. We can clarify the appropriate clinic and the questions about local medicine access and follow-up before you travel. The useful outcome is a treatment comparison you can act on, with a clear plan for obtaining and monitoring the selected medicine where you will live.
Sources and references: [4]
Common questions
Are biologics free of serious side effects?
No medicine is risk-free. Each biologic has its own safety profile; for example, dupilumab can cause eye symptoms and injection-site reactions. Ask about the specific drug and your medical history.
Sources and references: [1]
Does the JAK warning mean nobody with eczema should use one?
No. A clinician weighs the expected benefit against individual risk factors and the alternatives. The warning makes careful selection and follow-up important; it is not a prediction that every patient will experience those events.
Can I stop all creams once systemic treatment starts?
Not automatically. Moisturizers and prescribed topical treatment may remain part of the plan. Ask which products to continue, which to use for flares and when the regimen will be reviewed.
Sources and references: [1]
Sources and references
- American Academy of Dermatology: Atopic dermatitis treatment
- American Academy of Dermatology: JAK inhibitors
- FDA: JAK inhibitor warnings about cardiovascular events, cancer, blood clots and death
- Huashan Hospital Affiliated to Fudan University
Prepared with AI assistance by EastMedGo for patients comparing treatment and care options.